Advances in Management of Acute Myeloid Leukemia
To begin the course, please login or register by clicking ENROLL. After logging in, you will be able to complete the pretest and view the video/documents. You will have the option to complete the posttest, evaluation and receive credit. Some courses may have an associated cost.
Starts On:
7/1/2019: 12:00 AM
Ends On:
11/20/2019: 12:00 AM
Session Type:
Internet Activity Enduring Material
Credits:
0.75
Description:
Rizwan Romee, MD
Assistant Professor, Oncology
BMT and Leukemia
Clinical Director, Haploidentical Transplant Program
Disclosures: No financial relationships to disclose.
Presenters should indicate if speaking off label. This activity originated as a presentation at the CME activity, Advances in Oncology & Hematology, September 8-9, 2017, which was supported in part by Celgene, Novartis Pharmaceuticals, Seattle Genetics, Takeda Oncology, and Lilly USA, LLC.
Holly S. Comer, NP, ANP-BC, Outpatient Nurse Practitioner
Disclosures: Dr. Comer is on the Speakers' Bureau for Celgene Corporation and Seattle Genetics
Ramaswamy Govindan, MD, Co-Chair, Professor of Medicine
Disclosures: Dr. Govindan does consulting for Celgene Corporation, Bayer Corporation, Roche, Glaxo Smithkline, Clovis Oncology, Boehringer Ingelheim, Helsinn Oncology, Genentech, Pfizer, Inc., Astra Zeneca, Abbvie, Inc., Inivata, and INC Research. He is on the Speakers' Bureau for Baxalta, Roche, and Abbvie, Inc.
Krystal F. Prater, RN, BSN, Nurse Coordinator
Disclosures: No financial relationships to disclose.
Saiama N. Waqar, MBBS, MSCI, Co-Chair, Assistant Professor of Medicine
Disclosures: No financial relationships to disclose.
Peter Westervelt, MD, PhD, Co-Chair, Professor of Medicine
Disclosures: No financial relationships to disclose.
Faculty
Rizwan Romee, MD
Assistant Professor, Oncology
BMT and Leukemia
Clinical Director, Haploidentical Transplant Program
Disclosures: No financial relationships to disclose.
Presenters should indicate if speaking off label. This activity originated as a presentation at the CME activity, Advances in Oncology & Hematology, September 8-9, 2017, which was supported in part by Celgene, Novartis Pharmaceuticals, Seattle Genetics, Takeda Oncology, and Lilly USA, LLC.
Planning Committee
Holly S. Comer, NP, ANP-BC, Outpatient Nurse Practitioner
Disclosures: Dr. Comer is on the Speakers' Bureau for Celgene Corporation and Seattle Genetics
Ramaswamy Govindan, MD, Co-Chair, Professor of Medicine
Disclosures: Dr. Govindan does consulting for Celgene Corporation, Bayer Corporation, Roche, Glaxo Smithkline, Clovis Oncology, Boehringer Ingelheim, Helsinn Oncology, Genentech, Pfizer, Inc., Astra Zeneca, Abbvie, Inc., Inivata, and INC Research. He is on the Speakers' Bureau for Baxalta, Roche, and Abbvie, Inc.
Krystal F. Prater, RN, BSN, Nurse Coordinator
Disclosures: No financial relationships to disclose.
Saiama N. Waqar, MBBS, MSCI, Co-Chair, Assistant Professor of Medicine
Disclosures: No financial relationships to disclose.
Peter Westervelt, MD, PhD, Co-Chair, Professor of Medicine
Disclosures: No financial relationships to disclose.
Objectives:
The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
- Highlight some of the recent advances in basic biology of AML
- Update the audience on some of the key recent clinical trials with promising results
- Discuss major indications for transplant eligibility
- Briefly update on 'alternate' donor outcomes after allogeneic transplant in AML patients
Additional Information:
Target Audience: This course is designed for intended for medical oncologists, and radiation oncologists, hematologists, as well as physician assistants, nurses and nurse practitioners.
Date
Publication Date: July 1, 2019
Expiration Date: December 12, 2019
Target Audience: This course is designed for intended for medical oncologists, and radiation oncologists, hematologists, as well as physician assistants, nurses and nurse practitioners.
Date
Publication Date: July 1, 2019
Expiration Date: December 12, 2019
Accreditation Information:
In support of improving patient care, Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Awarded for this Activity:
In support of improving patient care, Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Awarded for this Activity:
Credit Statement:
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
References:
- Bloomfield et al. Blood 2017 129:424-447
- Feldman EJ et al. J Clin Oncol. 2011;29(8):979–985
- Garcia-Manero et al ASH Blood 2016 128:3548
- Lim WS et al. Leuk Res. 2010;34(9):1245–1223
Disclosure Information:
It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and resolved.
Presenters are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis. These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the provider for CME credits.
Presenters are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis. These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the provider for CME credits.
